Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 20/20 | 0.52 |
| ▸ | S1PR5 | Q9H228 | 6/20 | 0.52 |
| ▸ | S1PR3 | Q99500 | 10/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21296010 | 1.00 | S1PR1 (0.52) | S1PR1S1PR5S1PR3 | |
| SCHEMBL21296003 | 0.96 | S1PR1 (0.57) | S1PR1S1PR5S1PR3 | |
| SCHEMBL30815917 | 0.96 | S1PR1 (0.57) | S1PR1S1PR5S1PR3 | |
| SCHEMBL30816215 | 0.96 | S1PR1 (0.57) | S1PR1S1PR5S1PR3 | |
| SCHEMBL21295990 | 0.96 | S1PR1 (0.57) | S1PR1S1PR5S1PR3 | |
| SCHEMBL21308980 | 0.96 | S1PR1 (0.57) | S1PR1S1PR5S1PR3 | |
| SCHEMBL21308794 | 0.94 | S1PR1 (0.61) | S1PR1S1PR5S1PR3 | |
| SCHEMBL21308436 | 0.94 | S1PR1 (0.61) | S1PR1S1PR5S1PR3 | |
| SCHEMBL21296030 | 0.94 | S1PR1 (0.61) | S1PR1S1PR5S1PR3 | |
| SCHEMBL30815961 | 0.94 | S1PR1 (0.61) | S1PR1S1PR5S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327342-A1 | COMPOUNDS HAVING S1P5 RECEPTOR AGONISTIC ACTIVITY | ONO PHARMACEUTICAL CO., LTD. (JP) | 2024-10-03 | — | — | US | disclosed |
| EP-4431157-A2 | 1-[[(3S)-3-METHYL-6-(4(4,4-TRIFLUOROBUTOXY)-3,4-DIHYDRONAPHTHALEN-2YL]METHYL]AZETIDINE-3-CARBOXYLIC ACID HAVING S1P5 RECEPTOR AGONIST ACTIVITY FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS AND CANCER | ONO Pharmaceutical Co., Ltd. (JP) | 2024-09-18 | — | — | EP | disclosed |
| US-12049445-B2 | Compounds having S1P5 receptor agonistic activity | ONO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-30 | — | — | US | disclosed |
| CN-111757869-B | Compounds having S1P5 receptor agonistic activity | 小野药品工业株式会社 | 2024-03-08 | — | — | CN | disclosed |
| US-11198672-B2 | Compounds having S1P5 receptor agonistic activity | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-12-14 | — | — | US | disclosed |
| US-20210087141-A1 | COMPOUNDS HAVING S1P5 RECEPTOR AGONISTIC ACTIVITY | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-03-25 | — | — | US | disclosed |
| EP-3757091-A1 | COMPOUND HAVING S1P5 RECEPTOR AGONIST ACTIVITY | ONO Pharmaceutical Co., Ltd. (JP) | 2020-12-30 | — | — | EP | disclosed |
| CN-111757869-A | Compounds having S1P5 receptor agonistic activity | 小野药品工业株式会社 | 2020-10-09 | — | — | CN | disclosed |
| WO-2019163917-A1 | COMPOUND HAVING S1P5 RECEPTOR AGONIST ACTIVITY | 小野薬品工業株式会社 | 2019-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12049445-B2 | Compounds having S1P5 receptor agonistic activity | S1PR5, S1PR1, S1PR4 | S1PR1 2/4885S1PR5 1/4885S1PR3 6/4885 |
| US-20240327342-A1 | COMPOUNDS HAVING S1P5 RECEPTOR AGONISTIC ACTIVITY | S1PR5, S1PR1, S1PR4 | S1PR1 2/4885S1PR5 1/4885S1PR3 6/4885 |
| US-11198672-B2 | Compounds having S1P5 receptor agonistic activity | S1PR5, S1PR1, S1PR4 | S1PR1 2/4885S1PR5 1/4885S1PR3 6/4885 |
| US-20210087141-A1 | COMPOUNDS HAVING S1P5 RECEPTOR AGONISTIC ACTIVITY | S1PR5, S1PR1, S1PR4 | S1PR1 2/4885S1PR5 1/4885S1PR3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.